A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma

European Journal of Cancer

Volumn 50, Issue 6, 2014, Pages 1084-1089

  Najjar, Y G ^a   Mittal, K ^b   Elson, P ^b   Wood, L ^b   Garcia, J A ^b   Dreicer, R ^b   Rini, B I ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Alternative dosing; Renal cell carcinoma; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; COMMON TOXICITY CRITERIA; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOTHYROIDISM; KIDNEY METASTASIS; LEUKOPENIA; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION;

ALTERNATIVE DOSING; RENAL CELL CARCINOMA; SUNITINIB;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HAND-FOOT SYNDROME; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84897097674     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.01.025     Document Type: Article

References (7)

1. Y.G. Najjar, and B.I. Rini Novel agents in renal carcinoma: a reality check Ther Adv Med Oncol 4 4 2012 183 194
2. R.J. Motzer, T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, and O. Rixe et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 2007 115 124
3. S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, and N. Lassau et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 1 2006 25 35
4. B.E. Houk, C.L. Bello, B. Poland, L.S. Rosen, G.D. Demetri, and R.J. Motzer Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 66 2 2010 357 371
5. R.J. Motzer, T.E. Hutson, M.R. Olsen, G.R. Hudes, J.M. Burke, and W.J. Edenfield et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma J Clin Oncol 30 12 2012 1371 1377
6. Bradley J. Atkinson SK, Xuemei Wang, Tharakeswara Bathala, John Perpich, Paul Gettys Corn et al. Outcomes associated with sunitinib alternative schedule compared to traditional schedule: a single-center experience. In: ASCO GU; 2013.
7. Georg A. Bjarnason NSB, Jennifer J. Knox, Christian K. Kollmannsberger, M. Neil Reaume. A phase-II multicenter study of the efficacy and safety of Sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer. In: ASCO; 2013; Chicago 2013.